Nausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea

Similar documents
Managing Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting

Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy

ANTIEMETIC GUIDELINES: MASCC/ESMO

Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017

Sue Faulkner, BSN RN OCN October 18, 2017 Updates from Congress 2017

Guideline Update on Antiemetics

Chemotherapy Induced Nausea and Vomiting

Why Patients Experience Nausea and Vomiting and What to Do About It

Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

ATTUALITÀ NEL CONTROLLO DELL EMESI

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

Student Project PRACTICE-BASED RESEARCH

Management of Nausea and Vomiting

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

Drug: Aprepitant (Emend ) Date of Review: 4/01/10

MASCC Guidelines for Antiemetic control: An update

See Important Reminder at the end of this policy for important regulatory and legal information.

Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients

Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

Chemotherapy-induced nausea and vomiting (CINV)

PERUGIA INTERNATIONAL CANCER CONFERENCE VII MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER

See Important Reminder at the end of this policy for important regulatory and legal information.

A systemic review and meta analysis of Aprepitant Combination Regimens (ACR) for prevention of Chemotherapy induced Nausea

Management of chemotherapyinduced nausea and vomiting

Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD

Pediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives

TRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

Conflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

Prophylaxis and Management of Chemotherapy-Induced Nausea and Vomiting: A Comparison of How the Experts Practice

Supportive care session 1:

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

Clinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid

Cigna Drug and Biologic Coverage Policy

Nausea and vomiting continue to be among the most. Putting Evidence Into Practice:

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK

Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.

Antiemetics: Guidelines, Interactions and more.

An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy

Review of Acupressure Studies for Chemotherapy-Induced Nausea and Vomiting Control

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines

ESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE

REVIEW THE IMPACT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ON THE DAILY FUNCTION AND QUALITY OF LIFE OF PATIENTS. Kimberly A. Noonan, RN, MS, AOCN*

MOLECULAR AND CLINICAL ONCOLOGY 2: , 2014

Drug Therapy Guidelines

Guidelines for the Use of Anti-Emetics with Chemotherapy

Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi

Prevention CINV (highly emetogenic) Prevention PONV

See Important Reminder at the end of this policy for important regulatory and legal information.

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting

I will be talking first just about the challenges of chemotherapy-induced nausea and vomiting.

9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.

Original. Key words : breast cancer, chemotherapy-induced nausea and vomiting, quality of life, Functional Living Index Emesis

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Corporate Medical Policy

Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories

4/26/2016. Disclosure. Institution. Objectives. Background. Background

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?

Clinical Roundtable Monograph

Over the past few years in oncology, there

David G. Frame, PharmD. he etiology of nausea and vomiting is multifactorial,

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice

Drug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting

Research Article. Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life

Nausea and Vomiting. Principles and Practice in End of Life Care November 2018

Supportive Care Select Topics Updated May 2017 by Dr. Charles Lim (PGY-5 Medical Oncology Resident, University of Toronto)

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy

Nausea and Vomiting in Palliative Care

Cancer Studies Open Access

Practical Management of Chemotherapy-Induced Nausea and Vomiting

Clinical Policy: Oral Antiemetics (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: Last Review Date: 05.18

9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting

Safety and efficacy of a continuous infusion, patient controlled antiemetic pump to facilitate outpatient administration of high-dose chemotherapy

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Antiemetics in chemotherapy

Scott Akin MD FAAFP

Chemotherapy-Related Nausea and Vomiting and Treatment-Related Nausea and Vomiting

Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

Clinical Tools and Resources for Self-Study and Patient Education

SECTION 1: FEELING SICK

An Old Dog with New Tricks? Olanzapine s Role in Chemotherapy Induced Nausea and Vomiting

Drug Class Review on Newer Antiemetics

ANTIEMETIC RESEARCH AND PROGRESS: Richard J. Gralla, MD, FACP Professor of Medicine Albert Einstein College of Medicine Bronx, New York

FINAL CDEC RECOMMENDATION

Nausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA

Ping-Tsung Chen, MD; Chuang-Chi Liaw, MD

Published Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology

Richard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY

Nausea and vomiting after chemotherapy: What you can do about it

Transcription:

Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN, RN, AOCN Marilyn Kayne,, BSN, RN, OCN Laurel Barbour, MSN, RN, AOCN Marita Ripple, RN Mary Pat Johnston, MS, RN, AOCN Patty LeRoy,, BSN, RN, OCN Roxanne McDaniel, PhD, RN Gail Mallory, PhD, RN, CNAA Outcome: Nausea and Vomiting Category: Symptom experience Activities aimed at decreasing the occurrence and distress of these symptoms Evidence- based summary also includes retching Focus on interventions of of nurses, including advance practice nurses Scope of the Problem Up to 80% of patients who receive chemotherapy experience nausea and vomiting (Berger & Clark- Snow, 2001) There is evidence that clinicians (MDs, RNs) still underestimate the likelihood that their patients will develop CINV, and may perceive control as better than it actually is (Grunberg( Grunberg,, et al, 2002, 2004) Berger, A. M., & Clark-Snow, R.A. (2001). Nausea and vomiting. In V.T. DeVita,, S., Hellman, & Rosenberg (Eds.), Cancer: Principles and practice of oncology (6 th Ed., pp. 2869-2880). 2880). Philadelphia: Lippincott Williams & Wilkins. Grunberg,, S.M., et al. (2002). Proc. Am Soc. Clin. Oncol,, 21: 250a. Grunberg,, S.M., et al. (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.. Cancer, 10, 2261-2268. 2268. Chemotherapy-Induced Nausea and Vomiting (CINV) Reviews limited to adult population (over 18 years of age) Studies limited to interventions for chemotherapy- induced nausea and vomiting Nausea and/or vomiting primary study variables Definition: Nausea an unpleasant feeling in the back of the throat and stomach that may or may not result in vomiting (NCCN, 2004) Common terms used to describe nausea include sick to my stomach, queasy, or butterflies.

Definition: Vomiting a forceful contraction of the abdominal (stomach) muscles to cause stomach contents to come up through the mouth (NCCN, 2004) Often confused with nausea, but is a separate symptom Frequently referred to as throwing up Definition: Retching a rhythmic and spasm- like contraction of the diaphragm and abdominal muscles (NCCN, 2001) Different symptom from nausea or vomiting Often referred to as dry heaves Often not measured in clinical studies Pharmacologic Interventions for Nausea and Vomiting Mainstay of treatment Need for interventions with each type of N/V: anticipatory, acute, delayed, and breakthrough nausea and vomiting Regimens based on emetogenicity of chemotherapy Need to consider other risk factors (age, gender, alcohol use, anxiety, history of CINV, history of N/V (pregnancy, motion sickness) Guidelines for CINV American Society of Clinical Oncology (ASCO,1999) American Society of Health-System Pharmacists (ASHP,1999) www.guideline.gov Multinational Association of Supportive Care in Cancer (MASCC,2002) National Comprehensive Cancer Network (NCCN, 2005) www.nccn.org Perugia International Consensus (2004-05) 05) Are You Currently Using Antiemetic Guidelines in your Practice? A. All of the time B. Some of the time (not consistently) C. Not at this time D. Not using, but would like to A. Yes B. No Are you limited to certain antiemetics in your practice?

NCCN Antiemesis Guidelines (2005) High emetic risk (Level 5) Moderate emetic risk (Level 3-3 4)4) Low emetic risk (Level 2) Minimal emetic risk (Level 1) All recommendations 2A unless otherwise noted NCCN Categories of Consensus Category 1: Uniform NCCN consensus, based on high- level evidence Category 2A: Uniform NCCN consensus, based on lower- level evidence including clinical experience Category 2B: Non- uniform consensus, based on lower- level evidence including clinical experience Category 3: major NCCN disagreement Definition: Acute-onset Nausea and Vomiting Nausea or vomiting which occurs a few minutes to several hours after drug administration, and commonly resolves with in the first 24 hours, with the intensity of emesis peaking at 5-5 6hours (NCCN, 2005) Risk Factors for Nausea and Vomiting: Gender (female) Young age (38 years) History of nausea with pregnancy (recently!) Anxiety (Fear of chemo and unknown future) Highly emetogenic chemotherapy (Cisplatin( and Etoposide) Lisa began chemotherapy with Cisplatin and Etoposide,, the first of 6 courses, with the following antiemetics: Palonosetron 0.25 mg IV thirty min. day 1 Aprepitant tri- pack (days 1-1 3) Dexamethasone (days 1-1 4) Ondansetron 8 mg po for home use prn Experienced mild- moderate nausea (tolerable for her), but more distressing was the feeling of agitation and paranoia Nervous, worried parents would drop her baby, went by Taco Bell and said at least ten times I want a chicken taco Offered to decrease dexamethasone,, but preferred to drop completely

Definition: Delayed Onset Nausea and Vomiting nausea or vomiting that occurs more than 24 hours after chemotherapy administration, and may last 6-6 7days (NCCN, 2005) Dilemma: Discontinue steroid, still with mild- moderate delayed nausea/vomiting Refer to NCCN guidelines (Olanzapine( Olanzapine) Input from pharmaceutical representative Literature search for evidence Discussion with physician Patient discussion Show Me the Evidence: Olanzapine (Zyprexa) Antipsychotic that blocks multiple neurotransmitters (dopamine and serotonin) Common side effects: sedation and weight gain, association with onset of diabetes Breakthrough treatment for N/V, 2.5-5mg PO bid prn (NCCN, 2005) Show Me the Evidence: Olanzapine (Zyprexa) Phase II study, 30 chemotherapy-naïve patients (23 women) receiving moderately or highly emetogenic chemotherapy Patients took oral olanzapine,, 5 mg/day for 2 days prior to chemotherapy, then 10 mg/day 1 (along with IV granisetron and dexamethasone), and 10 mg/day days 2-55 (along with oral dexamethasone Navari,, et al (2005). A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Support Care Cancer,, 13 (7), 529-534. 534. Show Me the Evidence: Olanzapine (Zyprexa) Complete response (no emesis, no rescue) was 100% for acute period, 80% for the delayed period (days 2-2 5) in 10 patients receiving highly emetogenic therapy Complete response was 100% for acute period, and 85% for the delayed period in 20 patients receiving moderately emetogenic therapy Navari,, R..M., et al (2005). Support Care Cancer, 13 (7), 529-534. 534. Show Me the Evidence: Olanzapine (Zyprexa) Nausea also well-controlled, no nausea (0 on scale 0-10) 0 in acute or delayed periods in patients receiving highly emetogenic chemotherapy 85% control in acute period, 65% control in delayed period in moderately emetogenic chemotherapy group No grade 3 or 4 toxicities Navari,, R.M. (2005). Support Care Cancer, 13 (7), 529-534. 534.

Case Study: Karen Karen is a 42 year old RN with breast cancer, beginning the first of four cycles of AC (Adriamycin,, Cyclophosphamide) chemotherapy Recently had breast reconstruction and had terrible nausea with anesthesia History of diabetes Case Study: Karen Karen was ordered to have a 5HT3 antagonist, low dose of dexamethasone on day 1 only, and 5HT3 for prn use She inquired about the use of ginger to help prevent nausea and vomiting Show Me the Evidence: Ginger 1 randomized controlled trial was conducted in 48 gynecologic oncology patients with ginger compared to metoclopramide Addition of ginger to standard antiemetic regimen in acute phase showed no advantage, and was comparable to metoclopramide in delayed phase Show Me the Evidence: Ginger Gaps: small sample, did not use newer 5- HT3 agents, dosing schedule borrowed from other uses Manusirivithaya,, S., et al. (2004). Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer,, 14, 1063-1069. 1069. Show Me the Evidence: Ginger 1 systematic review (6 studies, 1 for chemotherapy- induced N/V) favored ginger over placebo CINV study of 41 patients with leukemia suggested a significant reduction in nausea in patients receiving ginger compared to placebo (P value not reported, study published in abstract only) Ernst, E. & Pittler,, M.H. (2000). Efficacy of ginger for nausea and vomiting: A systematic s review of randomized clinical trials. British Journal of Anaesthesia,, 84 (3), 367-71. 71. Show Me the Evidence: Ginger No reports of adverse reactions to ginger Data insufficient to draw firm conclusions Few studies for CINV National Center for Complementary and Alternative Medicine currently studying ginger in CINV

What would be your response when Karen inquired about the use of ginger? A. Would definitely recommend B. Would consider with caution C. Would definitely not recommend Case Study: Karen After review of this evidence, discussed pros and cons of ginger Patient opted to try ginger, purchased at local health food store Took at doses in article, 1 gram/day for 5 days Verbalizes some improvement, offers to family members Definition: Anticipatory Nausea and Vomiting The occurrence of nausea and/or vomiting before patients receive their next chemotherapy treatment, often due to a negative past experience with chemotherapy (NCCN, 2005) Anticipatory Nausea and Vomiting Due to ineffective treatment of chemotherapy-induced nausea Treatment may be delayed, doses reduced, or discontinued, all which can affect survival Pharmacologic interventions (alprazolam( & lorazepam) Behavioral techniques: relaxation/systematic desensitization, hypnosis/guided imagery, music therapy, acupressure NCCN, 2005. Eckert, R.M. (2001). Understanding anticipatory nausea. ONF,, 28 (10), 1553-1558. Despite better control of nausea and vomiting, she still dreaded coming in for 3 days of chemotherapy every 3 weeks The thought of coming to the treatment center, the smell, the staff, and the beverages made her queasy, nauseous, and she even vomited prior to her treatment in the 4 th cycle Slide Not Available

How might you approach the anticipatory N/V based on the current evidence? A. Consider pharmacologic interventions B. Consider non- pharmacologic interventions C. Consider A and B D. Consider changing chemotherapy agents What did we do? Prescribed Lorazepam 1 mg twice a day, with doses the night before and the morning of treatment Provided alternative beverages Discussed relaxation and imagery techniques to provide diversion Show Me the Evidence: Acupressure Acupressure used in a pilot study of 17 women with breast cancer Intervention involved finger acupressure bilaterally at the P6 (forearm) and ST36 (knee) Acupressure group reported significantly less intensity and experience of nausea Show Me the Evidence: Acupressure Gaps: Small sample study needs replication May be most practical, could be taught to patients, not costly Dibble, et al. (2000). Acupressure for Nausea: Results of a pilot study. ONF,, 27 (1), 41-47. 47. Definition: Breakthrough Emesis Emesis that occurs despite prophylactic treatment and requires rescue (NCCN, 2005) Where would be appropriate places to search for alternative antiemetics for breakthrough or delayed N/V? A. Standardized guidelines B. Pubmed search for latest regimens C. Query your colleagues D. All of the above

Show Me the Evidence: Cannabinoids Across all trials, cannabinoids were more effective than active comparators and placebo At the end of 18 crossover trials, 38-90% of patients preferred cannabinoids In selected patients, cannabinoids are useful as mood-enhancing adjuvants More side effects with cannabinoids Tramer,, et al. (2003). Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ,, 323 (7303), 16-21. Show Me the Evidence: Cannabinoids Gaps: No comparisons of cannabinoids with a serotonin receptor antagonist (5-HT3) Tramer,, et al (2003). Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ,, 323 (7303), 16-21. Definition: Refractory Emesis Emesis which occurs after prophylactic treatment fails, and the patient no longer responds to treatment to prevent nausea and vomiting (NCCN, 2005) Future Directions Research related to symptom clusters Acupressure and acupuncture studies ongoing Need for randomized intervention studies of complementary and alternative medicine Need more nursing studies Future Directions Based on study of family relationships on adjustment to chemotherapy, family member conflicts can worsen symptoms (nausea), especially in women and younger adults Family intervention studies to evaluate effectiveness in reducing the development and duration of anticipatory symptoms Kim, Y. & Morrow, G.R. (2003). Changes in family relationships affect the development of chemotherapy-related related nausea symptoms. Support Care Cancer,, 11, 171-177. 177. Issues for Nursing Knowledge of and barriers to adherence to CINV guidelines Feasibility of utilizing selected interventions (access, cost) Time constraints to educate patients or to perform the interventions While drug therapy remains essential, how can we improve the N/V outcomes?

Nausea and Vomiting Some men see things as they are and say Why? I dream of things that never were and say, Why not? -- Robert Frost ONS Website Reference http://onsopcontent.ons.org/toolkits/evide nce/clinical/summaries.shtml#nv